Immunoprecise Antibodies Stock Revenue
| IPA Stock | USD 0.38 0.03 8.57% |
Immunoprecise Antibodies fundamentals help investors to digest information that contributes to Immunoprecise Antibodies' financial success or failures. It also enables traders to predict the movement of Immunoprecise Stock. The fundamental analysis module provides a way to measure Immunoprecise Antibodies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunoprecise Antibodies stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 24.5 M | 25.7 M |
Immunoprecise | Revenue |
Immunoprecise Antibodies Company Revenue Analysis
Immunoprecise Antibodies' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Immunoprecise Antibodies Revenue | 24.52 M |
Most of Immunoprecise Antibodies' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunoprecise Antibodies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Immunoprecise
Projected quarterly revenue analysis of Immunoprecise Antibodies provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Immunoprecise Antibodies match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Immunoprecise Antibodies' stock price.
Immunoprecise Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunoprecise Antibodies is extremely important. It helps to project a fair market value of Immunoprecise Stock properly, considering its historical fundamentals such as Revenue. Since Immunoprecise Antibodies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunoprecise Antibodies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunoprecise Antibodies' interrelated accounts and indicators.
| 0.93 | 0.91 | 0.2 | 0.11 | -0.5 | ||
| 0.93 | 0.99 | 0.14 | 0.18 | -0.53 | ||
| 0.91 | 0.99 | 0.13 | 0.2 | -0.52 | ||
| 0.2 | 0.14 | 0.13 | -0.37 | -0.59 | ||
| 0.11 | 0.18 | 0.2 | -0.37 | 0.35 | ||
| -0.5 | -0.53 | -0.52 | -0.59 | 0.35 |
Click cells to compare fundamentals
Immunoprecise Revenue Historical Pattern
Today, most investors in Immunoprecise Antibodies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunoprecise Antibodies' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immunoprecise Antibodies revenue as a starting point in their analysis.
Immunoprecise Antibodies Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Immunoprecise Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Immunoprecise Antibodies reported 24.52 M of revenue. This is 99.68% lower than that of the Biotechnology sector and 96.7% lower than that of the Health Care industry. The revenue for all United States stocks is 99.74% higher than that of the company.
Immunoprecise Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunoprecise Antibodies' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunoprecise Antibodies could also be used in its relative valuation, which is a method of valuing Immunoprecise Antibodies by comparing valuation metrics of similar companies.Immunoprecise Antibodies is currently under evaluation in revenue category among its peers.
Immunoprecise Antibodies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunoprecise Antibodies from analyzing Immunoprecise Antibodies' financial statements. These drivers represent accounts that assess Immunoprecise Antibodies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunoprecise Antibodies' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 49.9M | 52.8M | 197.4M | 140.7M | 86.7M | 45.2M | |
| Enterprise Value | 47.3M | 54.7M | 159.1M | 113.3M | 85.6M | 55.4M |
Immunoprecise Antibodies Institutional Holders
Institutional Holdings refers to the ownership stake in Immunoprecise Antibodies that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunoprecise Antibodies' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunoprecise Antibodies' value.| Shares | Xtx Topco Ltd | 2024-06-30 | 12.7 K | Ubs Group Ag | 2024-06-30 | 12.2 K | Mariner Wealth Advisors Llc | 2024-06-30 | 10 K | Simplex Trading, Llc | 2024-06-30 | 7.6 K | Citadel Advisors Llc | 2024-06-30 | 5.1 K | Group One Trading, Lp | 2024-06-30 | 2.4 K | West Paces Advisors Inc | 2024-09-30 | 1.7 K | Citigroup Inc | 2024-06-30 | 7.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Ingalls & Snyder Llc | 2024-06-30 | 1.3 M | Renaissance Technologies Corp | 2024-09-30 | 60.3 K |
Immunoprecise Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (1.15) % | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 19.56 M | ||||
| Shares Outstanding | 28.83 M | ||||
| Shares Owned By Insiders | 12.05 % | ||||
| Shares Owned By Institutions | 6.50 % | ||||
| Number Of Shares Shorted | 666.14 K | ||||
| Price To Book | 0.46 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 24.52 M | ||||
| Gross Profit | 11.56 M | ||||
| EBITDA | (22.95 M) | ||||
| Net Income | (27.18 M) | ||||
| Cash And Equivalents | 19.24 M | ||||
| Cash Per Share | 0.77 X | ||||
| Total Debt | 13.68 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.06 X | ||||
| Book Value Per Share | 1.20 X | ||||
| Cash Flow From Operations | (4.25 M) | ||||
| Short Ratio | 0.73 X | ||||
| Earnings Per Share | (0.77) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 72 | ||||
| Beta | 0.27 | ||||
| Market Capitalization | 10.84 M | ||||
| Total Asset | 59.99 M | ||||
| Retained Earnings | (100.27 M) | ||||
| Working Capital | 3.36 M | ||||
| Net Asset | 59.99 M |
About Immunoprecise Antibodies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunoprecise Antibodies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunoprecise Antibodies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunoprecise Antibodies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:Check out Immunoprecise Antibodies Piotroski F Score and Immunoprecise Antibodies Altman Z Score analysis. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 0.921 | Quarterly Revenue Growth (0.07) | Return On Assets (0.13) | Return On Equity (0.64) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.